Eqis Capital Management buys $6,125,870 stake in Gilead Sciences (GILD)

Gilead Sciences (GILD) : Eqis Capital Management scooped up 4,415 additional shares in Gilead Sciences during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Jul 14, 2016. The investment management firm now holds a total of 70,469 shares of Gilead Sciences which is valued at $6,125,870.Gilead Sciences makes up approximately 0.40% of Eqis Capital Management’s portfolio.

Other Hedge Funds, Including , Barry Investment Advisors boosted its stake in GILD in the latest quarter, The investment management firm added 224 additional shares and now holds a total of 3,314 shares of Gilead Sciences which is valued at $288,086. Gilead Sciences makes up approx 0.11% of Barry Investment Advisors’s portfolio. First Hawaiian Bank sold out all of its stake in GILD during the most recent quarter. The investment firm sold 2,823 shares of GILD which is valued $242,072. Investment Partners Ltd Oh Adv sold out all of its stake in GILD during the most recent quarter. The investment firm sold 2,628 shares of GILD which is valued $225,351.Laurel Wealth Advisors reduced its stake in GILD by selling 1,660 shares or 22.47% in the most recent quarter. The Hedge Fund company now holds 5,727 shares of GILD which is valued at $495,672. Gilead Sciences makes up approx 0.24% of Laurel Wealth Advisors’s portfolio.

Gilead Sciences opened for trading at $86.94 and hit $87.34 on the upside on Monday, eventually ending the session at $86.93, with a gain of 0.30% or 0.26 points. The heightened volatility saw the trading volume jump to 67,88,252 shares. Company has a market cap of $115,775 M.

On the company’s financial health, Gilead Sciences reported $3.03 EPS for the quarter, missing the analyst consensus estimate by $ -0.10 based on the information available during the earnings call on Apr 28, 2016. Analyst had a consensus of $3.13. The company had revenue of $7794.00 million for the quarter, compared to analysts expectations of $8065.42 million. The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $2.94 EPS.

Many Wall Street Analysts have commented on Gilead Sciences. Gabelli & Co Initiated Gilead Sciences on Jun 1, 2016 to “Buy”, Price Target of the shares are set at $109.Gilead Sciences was Downgraded by Maxim Group to ” Hold” on Apr 29, 2016. Shares were Reiterated by UBS on Apr 29, 2016 to “Buy” and Lowered the Price Target to $ 118 from a previous price target of $130 .

Gilead Sciences Inc. (Gilead) is a research-based biopharmaceutical company that discovers develops and commercializes innovative medicines. The Company’s primary areas of focus include human immunodeficiency virus (HIV) liver diseases such as chronic hepatitis C virus (HCV) infection and chronic hepatitis B virus (HBV) infection oncology and inflammation and serious cardiovascular and respiratory conditions. The Company’s HIV products include Stribild Complera/Eviplera Atripla Truvada Viread Emtriva Tybost and Vitekta. Its Liver Diseases products include Harvoni Sovaldi Viread and Hepsera. Zydelig is the Company’s oncology product. Its Cardiovascular products include Letairis Ranexa and Lexiscan/Rapiscan. Its Respiratory products include Cayston and Tamiflu. Its other products include AmBisome and Macugen.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *